Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2010

View Archived Issues

Clinical data indicate RTS,S/AS01E malaria vaccine is safe in infants and children

Phase I/IIa trial evaluates prime-boost vaccination with AdCh63-MSP1 and MVA-MSP1 malaria vaccines

Phase I/II trial shows safety of PfSPZ malaria vaccine in healthy volunteers

Neuraltus Pharma receives grants under QTDP

Pevion Biotech reports preliminary data from phase I PEV-7 trial

Flt3L level in CSF is putative biomarker for primary fibromyalgia and Sjogren's syndrome

Genome-wide meta-analysis suggests involvement of PGC-1-alpha in Parkinson's disease

Wyeth discovers new inhibitors of PI3K-alpha and mTOR

S-47445 to advance to phase I trials for neurogenerative diseases

Eisai claims novel cytidine deaminase inhibitors

Resolve Therapeutics licenses agents for autoimmune disease from University of Washington

Forest Labs and Janssen collaborate on Bystolic and Savella

GlobeImmune receives Federal Therapeutic Discovery Project Program grants

Emergent BioSolutions receives grants for oncology and autoimmunity programs

Pfizer claims new agonists of prostanoid EP2 and EP4 receptors

Infinity Pharma patents new inhibitors of fatty-acid amide hydrolase 1

Oligomerix obtains phase II NIH grant for Alzheimer's disease drug discovery

Ceregene raises funds to further develop CERE-120 and CERE-110

Merck Serono's Saizen recommended for approval in Europe

Cerulean Pharma closes series C financing led by Lilly Ventures

Epeius Biotech gets U.S. federal grant to further develop Rexin-G

Aires Pharma completes series B financing and enters option agreement with Novartis

Santarus launches Cycloset in U.S. to improve glycemic control in type 2 diabetes

Bausch & Lomb begins phase IIb trial of BOL-303259-X for reduction of intraocular pressure

Enrollment complete in phase IIb trial of V-5 immunitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...